@article {Steinle10, author = {Nathan C Steinle and Naina Gupta and Alex Yuan and Rishi P Singh}, title = {Oral rifampin utilisation for the treatment of chronic multifocal central serous retinopathy}, volume = {96}, number = {1}, pages = {10--13}, year = {2012}, doi = {10.1136/bjophthalmol-2011-300183}, publisher = {BMJ Publishing Group Ltd}, abstract = {Chronic central serous retinopathy (CSR) is characterised by frequent exacerbations and a poor visual prognosis. Very few therapies exist for chronic CSR, and the existing therapies are often ineffective. Thus, novel therapies to combat this frustrating disorder are needed. Presented here is a case detailing a patient with chronic CSR with persistent subfoveal fluid of 2 years{\textquoteright} duration that completely resolved with 1 month of oral rifampin therapy. As a cytochrome P450, 3A4 inducer, rifampin is thought to favourably alter the metabolism of endogenous steroids, thereby leading to an improvement in CSR manifestations.}, issn = {0007-1161}, URL = {https://bjo.bmj.com/content/96/1/10}, eprint = {https://bjo.bmj.com/content/96/1/10.full.pdf}, journal = {British Journal of Ophthalmology} }